Batoclimab, a experimental antibody targeting the IL-15 receptor, is emerging as a encouraging clinical option for individuals living with refractory ulcerative colitis and have not responded adequately to standard treatments. Early clinical data suggest that batoclimab can considerably reduce inflammation and enhance disease activity, perhaps deli